| Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms |
38 |
| Current treatment options for meningioma |
26 |
| Microbiota-gut brain axis involvement in neuropsychiatric disorders |
20 |
| An update on ketamine and its two enantiomers as rapid-acting antidepressants |
19 |
| BACE inhibitors in clinical development for the treatment of Alzheimer's disease |
19 |
| Long-term effects of internet-supported cognitive behaviour therapy |
16 |
| Immune-based strategies for mood disorders: facts and challenges |
13 |
| Gut microbiota in ALS: possible role in pathogenesis? |
13 |
| Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis |
13 |
| Oxidative stress in epilepsy |
12 |
| Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review |
11 |
| Biomarkers for bipolar disorder: current status and challenges ahead |
11 |
| Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel |
11 |
| Neuroimaging in amyotrophic lateral sclerosis: current and emerging uses |
10 |
| Therapies for mobility disability in persons with multiple sclerosis |
10 |
| Multidisciplinary care for people with Parkinson's disease: the new kids on the block! |
10 |
| Intracerebral hemorrhage: an update on diagnosis and treatment |
10 |
| mTOR dysregulation and tuberous sclerosis-related epilepsy |
9 |
| Neurocysticercosis: the good, the bad, and the missing |
9 |
| Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics |
9 |
| Tourette syndrome and other chronic tic disorders: an update on clinical management |
9 |
| An update on the diagnosis and treatment of vestibular schwannoma |
9 |
| Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies |
8 |
| Identifying risk factors for cognitive issues in multiple sclerosis |
8 |
| Technology-based assessment of motor and nonmotor phenomena in Parkinson disease |
8 |
| Edaravone for the treatment of amyotrophic lateral sclerosis |
8 |
| Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities |
8 |
| Cerebral amyloid angiopathy: diagnosis and potential therapies |
7 |
| Surgical treatment of dystonia |
7 |
| Diagnostic challenges in rapidly progressive dementia |
7 |
| An update on NMDA antagonists in depression |
7 |
| Timing use of novel anti-epileptic drugs: is earlier better? |
6 |
| Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective |
6 |
| Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies |
6 |
| Dysautonomia in the pathogenesis of migraine |
6 |
| Sleep disorders and the risk of stroke |
6 |
| Advances in autoimmune myasthenia gravis management |
6 |
| Current and emerging ALS biomarkers: utility and potential in clinical trials |
6 |
| Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need |
6 |
| Treatment options for chorea |
6 |
| Non-conventional compounds with potential therapeutic effects against Alzheimer's disease |
6 |
| Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD |
6 |
| Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment |
5 |
| Neuromodulation for the treatment of primary headache syndromes |
5 |
| Developing therapeutic strategies to promote myelin repair in multiple sclerosis |
5 |
| Implications of structural and functional brain changes in amyotrophic lateral sclerosis |
5 |
| An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges |
5 |
| Identifying and mitigating Sudden Unexpected Death in Epilepsy (SUDEP) risk factors |
5 |
| Fremanezumab as a preventive treatment for episodic and chronic migraine |
5 |
| The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease |
5 |
